Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Minocycline controlled-release - OraPharma

Drug Profile

Minocycline controlled-release - OraPharma

Alternative Names: Arestin; Arestin LCM; Minocycline microspheres

Latest Information Update: 14 Sep 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer OraPharma; Wyeth
  • Class Amides; Anti-inflammatories; Antiacnes; Antibacterials; Dimethylamines; Eye disorder therapies; Neuroprotectants; Skin disorder therapies; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Periodontitis
  • Discontinued Peri-implantitis

Most Recent Events

  • 09 Aug 2016 Discontinued - Phase-III for Peri-implantitis in United Kingdom, Sweden, Germany and USA (Subgingival) based on analysis of a phase III study data (Valeant Pharmaceuticals Form10-Q, August 2016)
  • 15 Mar 2016 Biomarkers information updated
  • 24 Jun 2014 OraPharma completes a phase III trial in Peri-implantitis in USA, United Kingdom, Germany & Sweden (NCT01539564)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top